Vertex up 3% after hours on Q4 beat, strong Trikafta launch

Vertex Pharmaceuticals (NASDAQ:VRTX) Q4 results:
Revenues: $1,413.3M (+62.4%); product sales: $1,413.3M (+62.8%).
Key product sales: Kalydeco: $236M (-8.9%); Orkambi: $270 (-14.3%); Symdeko/Symkevi: $332M (+12.9%); Trikafta: $420M.
Net income: $583.2M (-61.8%); non-GAAP net income: $444.3M (+31.9%); EPS: $2.23 (-62.6%); non-GAAP EPS: $1.70 (+30.8%).
2020 guidance: Product sales: $5.1B – 5.3B from $3.70B – 3.75B.
Shares up 3% after hours.
https://seekingalpha.com/news/3536513-vertex-up-3-after-hours-on-q4-beat-strong-trikafta-launch